it’s evident that NNZ2591 is a superior drug. In the recent interview with Hashan, he used Neuren as an example to demonstrate that Aussie biotechs often lack the financials to push through the trials with their assets. In the case of Neuren, rather than focusing on the most promising drug NNZ2591 initially, Neuren had to prioritise Trofinetide as it was more progressed and less financials were required
Neuren - where to from here ?, page-72
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.80 |
Change
0.460(2.16%) |
Mkt cap ! $2.783B | |||
| Open | High | Low | Value | Volume |
| $21.50 | $22.27 | $21.49 | $17.34M | 792.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 3550 | $21.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.81 | 567 | 1 |
View Market Depth
| Last trade - 16.10pm 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$21.85 |
Change
0.460 ( 2.27 %) |
||||
| Open | High | Low | Volume | ||
| $21.56 | $22.26 | $21.50 | 182893 | ||
| Last updated 15.59pm 16/05/2024 ? | |||||
| NEU (ASX) Chart |